DALLAS, Jan. 14, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Biodel Inc. (Nasdaq:BIOD). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at:
Biodel Inc. (BIOD) is a development-stage biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. It develops its product candidates by applying its proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles. BIOD's most advanced product candidate is Linjeta (formerly known as VIAject). The Company has formulated Linjeta as a rapid-acting mealtime insulin for the treatment of patients with type I and type II diabetes. Earlier stage product candidates include follow-on and second generation rapid-acting mealtime insulins or insulin analogs, VIAtab, a sublingual tablet formulation of insulin, a line of basal insulins, and a stabilized formulation of glucagon.
For only $19 a month, you can sign up for our real-time stock alert service. Click here to join now:
In the report, the analyst notes:
"Shares of BIOD soared ahead of the biotech company's presentation at JPMorgan's annual healthcare conference in San Francisco Thursday. The Company was expected to provide a corporate update, which includes information about the development of new follow-on formulations of its lead product, Linjeta, including milestones and timelines.
"BIOD is trading above its 20-day moving average. This is considered to be the sign of a bullish trend. There is added weight to this indication because the moving average is rising and suggests that there has been buying interest in this stock."
To read the entire report visit:
See what investors are saying about BIOD at
Get breaking news on BIOD at
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit:
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.
CONTACT: Brian Johnson info@microstockprofit.com 1-888-307-2850